Synthetic Biologics, Inc.
AMEX: SYN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven Shallcross
- Employees
- 16
- Headquarters
- Rockville, United States
- IPO year
- 1993
- Market cap
- $16.2M
- Website
- https://www.syntheticbiologics.com
Loading SYN…
Loading profile data…Frequently asked questions about SYN
What does Synthetic Biologics, Inc. (SYN) do?
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent...
Where does SYN trade?
Synthetic Biologics, Inc. (SYN) trades on the New York Stock Exchange Arca.
What sector is SYN in?
Synthetic Biologics, Inc. (SYN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Synthetic Biologics, Inc.?
Steven Shallcross is the chief executive officer of Synthetic Biologics, Inc. (SYN).
Where is Synthetic Biologics, Inc. headquartered?
Synthetic Biologics, Inc. is headquartered in United States.
Does SYN pay a dividend?
Synthetic Biologics, Inc. (SYN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SYN go public?
Synthetic Biologics, Inc. (SYN) completed its initial public offering in 1993.